Poor Countries Fall Behind In Race To Reserve COVID-19 Vaccine

НОВОРОССИЯ.RU
05 Ноя 2020, 20:18

Enlarge this image

Health workers measure a woman’s blood pressure during a simulation of a COVID-19 vaccine trial in Indonesia.

Adriana Adie/NurPhoto via Getty Images

hide caption

toggle caption

Adriana Adie/NurPhoto via Getty Images

Shots — Health News
Advisers To CDC Debate How COVID-19 Vaccine Should Be Rolled Out

Not all of the candidate vaccines will work. And so rich countries are hedging their bets by reserving more than one candidate, says Dr. Krishna Udayakumar, who led the study at Duke University.

This just-in-case strategy has an upside: «It’s flooding investment into vaccine development and allowing many more candidates to be developed than otherwise would be possible,» he says.

But the strategy also has a downside: It will likely greatly delay vaccine distribution in poor countries. «We could be looking at two to four years before a general population in low-income countries really have a vaccine available,» Udayakumar says.

To generate these predictions, Udayakumar and his colleagues pulled together all publicly available data about vaccine agreements between countries and pharmaceutical companies. Their findings, published last Thursday on the Web, point to glaring inequalities in acquiring the vaccine.

Several countries, including the U.S., Canada and the U.K. as well as members of the EU, are reserving enough potential doses of different types of vaccines to immunize their entire populations several times before some poor countries have any vaccine at all. For example, the U.S. and the U.K. will potentially have enough to cover its population four times over. And Canada could have enough to immunize its population five times.

At the same time, several of these countries, including Canada and the U.K., recently joined an international initiative to help distribute the vaccine more equally around the world and to help bring vaccine to countries who can’t produce or purchase it themselves. (The U.S. hasn’t yet joined the agreement.)

That initiative, called COVAX, aims to have 2 billion doses available by the end of next year. So far, it has reserved about 740 million doses.

But there are potential stumbling blocks. There’s no guarantee those doses will work in many poor places, says Amanda Glassman, executive director of the Center for Global Development. Or that the countries in question will have the funds for any requested payment from COVAX.

«One concern that I have with COVAX is that it’s committed to purchasing vaccines that could be too expensive or inappropriate for low- and middle-income countries,» Glassman says. For instance, the vaccine could require special freezers for storage or multiple doses to be effective.

«Hopefully, that doesn’t happen,» she adds. «But COVAX could possibly be stuck paying for some vaccine that would not be particularly usable in countries that need it.»